The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Papillomavirus Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Human papilloma virus (HPV) vaccine is a vaccine that prevents infection by certain types of human papillomavirus.
The global Human Papillomavirus Vaccine market size is expected to reach US$ 2699.8 million by 2029, growing at a CAGR of 2.8% from 2023 to 2029. The market is mainly driven by the significant applications of Human Papillomavirus Vaccine in various end use industries. The expanding demands from the Cervical Cancer, Anal Cancer, Penile Cancer and Oropharyngeal Cancer, are propelling Human Papillomavirus Vaccine market. Bivalent, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Quadrivalent segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Papillomavirus Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Papillomavirus Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Papillomavirus Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Papillomavirus Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Papillomavirus Vaccine covered in this report include Merck, GlaxoSmithKline, Sanofi, Johnson & Johnson, AstraZeneca, Serum Institute, Wantai Biological, KM Biologics and Bharat Biotech, etc.
The global Human Papillomavirus Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
GlaxoSmithKline
Sanofi
Johnson & Johnson
AstraZeneca
Serum Institute
Wantai Biological
KM Biologics
Bharat Biotech
Global Human Papillomavirus Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Papillomavirus Vaccine market, Segment by Type:
Bivalent
Quadrivalent
Nonavalent
Global Human Papillomavirus Vaccine market, by Application
Cervical Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer
Genital Warts
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Papillomavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Human papilloma virus (HPV) vaccine is a vaccine that prevents infection by certain types of human papillomavirus.
The global Human Papillomavirus Vaccine market size is expected to reach US$ 2699.8 million by 2029, growing at a CAGR of 2.8% from 2023 to 2029. The market is mainly driven by the significant applications of Human Papillomavirus Vaccine in various end use industries. The expanding demands from the Cervical Cancer, Anal Cancer, Penile Cancer and Oropharyngeal Cancer, are propelling Human Papillomavirus Vaccine market. Bivalent, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Quadrivalent segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Papillomavirus Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Papillomavirus Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Papillomavirus Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Papillomavirus Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Papillomavirus Vaccine covered in this report include Merck, GlaxoSmithKline, Sanofi, Johnson & Johnson, AstraZeneca, Serum Institute, Wantai Biological, KM Biologics and Bharat Biotech, etc.
The global Human Papillomavirus Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
GlaxoSmithKline
Sanofi
Johnson & Johnson
AstraZeneca
Serum Institute
Wantai Biological
KM Biologics
Bharat Biotech
Global Human Papillomavirus Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Papillomavirus Vaccine market, Segment by Type:
Bivalent
Quadrivalent
Nonavalent
Global Human Papillomavirus Vaccine market, by Application
Cervical Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer
Genital Warts
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Papillomavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Human Papillomavirus Vaccine Market Overview
1.1 Human Papillomavirus Vaccine Product Overview
1.2 Human Papillomavirus Vaccine Market Segment by Type
1.2.1 Bivalent
1.2.2 Quadrivalent
1.2.3 Nonavalent
1.3 Global Human Papillomavirus Vaccine Market Size by Type
1.3.1 Global Human Papillomavirus Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Human Papillomavirus Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Human Papillomavirus Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Papillomavirus Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Human Papillomavirus Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Human Papillomavirus Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Human Papillomavirus Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Human Papillomavirus Vaccine Sales Breakdown by Type (2018-2023)
2 Global Human Papillomavirus Vaccine Market Competition by Company
2.1 Global Top Players by Human Papillomavirus Vaccine Sales (2018-2023)
2.2 Global Top Players by Human Papillomavirus Vaccine Revenue (2018-2023)
2.3 Global Top Players by Human Papillomavirus Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Human Papillomavirus Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Papillomavirus Vaccine Market Competitive Situation and Trends
2.5.1 Human Papillomavirus Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Papillomavirus Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Papillomavirus Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Human Papillomavirus Vaccine Market
2.8 Key Manufacturers Human Papillomavirus Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Papillomavirus Vaccine Status and Outlook by Region
3.1 Global Human Papillomavirus Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Human Papillomavirus Vaccine Historic Market Size by Region
3.2.1 Global Human Papillomavirus Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Human Papillomavirus Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Human Papillomavirus Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Human Papillomavirus Vaccine Forecasted Market Size by Region
3.3.1 Global Human Papillomavirus Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Human Papillomavirus Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Human Papillomavirus Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Human Papillomavirus Vaccine by Application
4.1 Human Papillomavirus Vaccine Market Segment by Application
4.1.1 Cervical Cancer
4.1.2 Anal Cancer
4.1.3 Penile Cancer
4.1.4 Oropharyngeal Cancer
4.1.5 Genital Warts
4.1.6 Others
4.2 Global Human Papillomavirus Vaccine Market Size by Application
4.2.1 Global Human Papillomavirus Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Human Papillomavirus Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Human Papillomavirus Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Papillomavirus Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Human Papillomavirus Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Human Papillomavirus Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Human Papillomavirus Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Human Papillomavirus Vaccine Sales Breakdown by Application (2018-2023)
5 North America Human Papillomavirus Vaccine by Country
5.1 North America Human Papillomavirus Vaccine Historic Market Size by Country
5.1.1 North America Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Human Papillomavirus Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Human Papillomavirus Vaccine Sales in Value by Country (2018-2023)
5.2 North America Human Papillomavirus Vaccine Forecasted Market Size by Country
5.2.1 North America Human Papillomavirus Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Human Papillomavirus Vaccine Sales in Value by Country (2024-2029)
6 Europe Human Papillomavirus Vaccine by Country
6.1 Europe Human Papillomavirus Vaccine Historic Market Size by Country
6.1.1 Europe Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Human Papillomavirus Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Human Papillomavirus Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Human Papillomavirus Vaccine Forecasted Market Size by Country
6.2.1 Europe Human Papillomavirus Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Human Papillomavirus Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Human Papillomavirus Vaccine by Region
7.1 Asia-Pacific Human Papillomavirus Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Human Papillomavirus Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Human Papillomavirus Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Human Papillomavirus Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Papillomavirus Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Human Papillomavirus Vaccine Sales in Value by Region (2024-2029)
8 Latin America Human Papillomavirus Vaccine by Country
8.1 Latin America Human Papillomavirus Vaccine Historic Market Size by Country
8.1.1 Latin America Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Human Papillomavirus Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Human Papillomavirus Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Human Papillomavirus Vaccine Forecasted Market Size by Country
8.2.1 Latin America Human Papillomavirus Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Human Papillomavirus Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Human Papillomavirus Vaccine by Country
9.1 Middle East and Africa Human Papillomavirus Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Human Papillomavirus Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Human Papillomavirus Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Human Papillomavirus Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Papillomavirus Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Human Papillomavirus Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Introduction and Business Overview
10.1.3 Merck Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Human Papillomavirus Vaccine Products Offered
10.1.5 Merck Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GlaxoSmithKline Human Papillomavirus Vaccine Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sanofi Human Papillomavirus Vaccine Products Offered
10.3.5 Sanofi Recent Development
10.4 Johnson & Johnson
10.4.1 Johnson & Johnson Company Information
10.4.2 Johnson & Johnson Introduction and Business Overview
10.4.3 Johnson & Johnson Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Johnson & Johnson Human Papillomavirus Vaccine Products Offered
10.4.5 Johnson & Johnson Recent Development
10.5 AstraZeneca
10.5.1 AstraZeneca Company Information
10.5.2 AstraZeneca Introduction and Business Overview
10.5.3 AstraZeneca Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AstraZeneca Human Papillomavirus Vaccine Products Offered
10.5.5 AstraZeneca Recent Development
10.6 Serum Institute
10.6.1 Serum Institute Company Information
10.6.2 Serum Institute Introduction and Business Overview
10.6.3 Serum Institute Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Serum Institute Human Papillomavirus Vaccine Products Offered
10.6.5 Serum Institute Recent Development
10.7 Wantai Biological
10.7.1 Wantai Biological Company Information
10.7.2 Wantai Biological Introduction and Business Overview
10.7.3 Wantai Biological Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Wantai Biological Human Papillomavirus Vaccine Products Offered
10.7.5 Wantai Biological Recent Development
10.8 KM Biologics
10.8.1 KM Biologics Company Information
10.8.2 KM Biologics Introduction and Business Overview
10.8.3 KM Biologics Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 KM Biologics Human Papillomavirus Vaccine Products Offered
10.8.5 KM Biologics Recent Development
10.9 Bharat Biotech
10.9.1 Bharat Biotech Company Information
10.9.2 Bharat Biotech Introduction and Business Overview
10.9.3 Bharat Biotech Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Bharat Biotech Human Papillomavirus Vaccine Products Offered
10.9.5 Bharat Biotech Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Papillomavirus Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Papillomavirus Vaccine Industrial Chain Analysis
11.4 Human Papillomavirus Vaccine Market Dynamics
11.4.1 Human Papillomavirus Vaccine Industry Trends
11.4.2 Human Papillomavirus Vaccine Market Drivers
11.4.3 Human Papillomavirus Vaccine Market Challenges
11.4.4 Human Papillomavirus Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Papillomavirus Vaccine Distributors
12.3 Human Papillomavirus Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
